Our goal was to quantify the dose-related effects of meloxicam treatment in the subchondral bone-involving, late phase of mono-iodoacetate-induced osteoarthritis, and to follow the levels of serum IL-6, IL-10 and TNFα, as markers of systemic inflammation. Here, IL10 is linked to osteoarthritis.